Shuen-Iu Hung Selected Research

Oxypurinol (Oxipurinol)

12/2015	Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin.
9/2015	Oxypurinol-Specific T Cells Possess Preferential TCR Clonotypes and Express Granulysin in Allopurinol-Induced Severe Cutaneous Adverse Reactions.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shuen-Iu Hung Research Topics

Disease

27	Stevens-Johnson Syndrome (Lyell's Syndrome) 01/2021 - 04/2004
17	Hypersensitivity (Allergy) 05/2024 - 01/2002
15	Cicatrix (Scar) 04/2024 - 03/2005
10	Drug Hypersensitivity (Drug Allergy) 01/2023 - 08/2007
9	Exanthema (Rash) 04/2024 - 02/2014
9	Neoplasms (Cancer) 04/2024 - 09/2011
8	Genetic Predisposition to Disease (Genetic Predisposition) 01/2021 - 03/2005
7	Drug-Related Side Effects and Adverse Reactions 04/2024 - 08/2005
7	Drug Hypersensitivity Syndrome 01/2021 - 03/2005
6	Eosinophilia 01/2019 - 02/2014
5	Necrosis 04/2024 - 12/2010
5	Gout 01/2023 - 03/2005
5	Inflammation (Inflammations) 01/2019 - 07/2002
5	Blister (Bulla) 01/2018 - 12/2008
5	Schizophrenia (Dementia Praecox) 11/2008 - 11/2005
4	Hyperuricemia 01/2016 - 03/2005
3	Acute Liver Failure (Fulminant Hepatic Failure) 01/2015 - 01/2011
2	Atopic Dermatitis (Atopic Eczema) 05/2024 - 11/2021
2	Alopecia (Baldness) 10/2023 - 01/2019
2	Infections 01/2021 - 05/2014
2	Epilepsy (Aura) 08/2020 - 04/2013
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2019 - 09/2015
2	Wounds and Injuries (Trauma) 01/2019 - 11/2014
2	Gouty Arthritis 01/2019 - 01/2017
2	Acute Generalized Exanthematous Pustulosis 05/2014 - 09/2010
1	Asthma (Bronchial Asthma) 05/2024
1	Anaphylaxis (Anaphylactic Shock) 04/2024
1	Ovarian Neoplasms (Ovarian Cancer) 12/2023
1	Skin Abnormalities 12/2023
1	Colorectal Neoplasms (Colorectal Cancer) 12/2023
1	COVID-19 10/2023
1	Alopecia Areata 10/2023
1	Dermatitis 02/2023
1	Mucositis 02/2023
1	Adenocarcinoma of Lung 02/2023
1	Delayed Hypersensitivity (Hypersensitivity, Type IV) 01/2023
1	Immediate Hypersensitivity 05/2022
1	Disseminated Intravascular Coagulation 06/2021
1	Drug Eruptions (Drug Eruption) 01/2021

Drug/Important Bio-Agent (IBA)

19	HLA-B Antigens (HLA-B)IBA 01/2021 - 04/2004
13	Carbamazepine (Tegretol)FDA LinkGeneric 01/2020 - 04/2004
12	HLA Antigens (Human Leukocyte Antigens)IBA 04/2024 - 04/2004
9	Proteins (Proteins, Gene)FDA Link 10/2023 - 07/2002
9	Allopurinol (Remid)FDA LinkGeneric 01/2020 - 03/2005
8	Peptides (Polypeptides)IBA 12/2023 - 03/2005
7	AntigensIBA 05/2024 - 09/2013
7	Anticonvulsants (Antiepileptic Drugs)IBA 01/2021 - 04/2006
6	T-Cell Antigen Receptors (T-Cell Receptor)IBA 05/2024 - 12/2011
6	Genetic Markers (Genetic Marker)IBA 04/2024 - 04/2004
5	CytokinesIBA 04/2024 - 09/2013
5	Anti-Bacterial Agents (Antibiotics)IBA 01/2023 - 03/2010
4	VaccinesIBA 10/2023 - 01/2018
4	EnzymesIBA 01/2023 - 11/2016
4	ChemokinesIBA 01/2023 - 09/2013
4	Biomarkers (Surrogate Marker)IBA 01/2019 - 12/2011
3	Immunoglobulin E (IgE)IBA 05/2024 - 11/2021
3	COVID-19 VaccinesIBA 10/2023 - 05/2022
3	DNA (Deoxyribonucleic Acid)IBA 04/2022 - 12/2013
3	Phenytoin (Dilantin)FDA LinkGeneric 08/2020 - 08/2014
2	Complementarity Determining Regions (Complementarity Determining Region)IBA 05/2024 - 09/2015
2	Adrenal Cortex Hormones (Corticosteroids)IBA 04/2024 - 01/2018
2	Tyrosine Kinase InhibitorsIBA 12/2023 - 02/2023
2	ZincIBA 12/2023 - 02/2023
2	Phosphotransferases (Kinase)IBA 12/2023 - 11/2014
2	ErbB Receptors (EGF Receptor)IBA 12/2023 - 02/2023
2	Excipients (Suspending Agents)IBA 10/2023 - 05/2022
2	Immune Checkpoint InhibitorsIBA 01/2021 - 10/2019
2	Cytochrome P-450 CYP2C9IBA 08/2020 - 01/2019
2	abacavir (Ziagen)FDA Link 01/2020 - 08/2007
2	HLA-B57 antigenIBA 01/2020 - 11/2019
2	HLA-A31 antigenIBA 01/2020 - 02/2014
2	Febuxostat FDA Link 01/2019 - 09/2015
2	Uric Acid (Urate)IBA 01/2019 - 01/2017
2	Oxypurinol (Oxipurinol)IBA 12/2015 - 09/2015
2	Sodium Chloride Symporter Inhibitors (Diuretics, Thiazide)IBA 08/2015 - 08/2014
2	perforin-granzyme BIBA 06/2012 - 12/2008
1	AllergensIBA 05/2024
1	Janus KinasesIBA 04/2024
1	Immunologic Factors (Immunomodulators)IBA 04/2024
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 04/2024
1	Tumor Biomarkers (Tumor Markers)IBA 12/2023
1	regorafenibIBA 12/2023
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 12/2023
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 02/2023
1	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 05/2022
1	Polysorbates (PSML)FDA Link 05/2022
1	anti-IgE antibodiesIBA 05/2022
1	Messenger RNA (mRNA)IBA 04/2022
1	dimethylamine (dimethylamine nitrate)IBA 11/2021
1	Filaggrin ProteinsIBA 11/2021
1	2-Propanol (Isopropyl Alcohol)FDA LinkGeneric 11/2021
1	ProcalcitoninIBA 06/2021
1	Sulfamethoxazole Drug Combination Trimethoprim (Co-Trimoxazole)FDA LinkGeneric 01/2021
1	micaIBA 01/2021
1	SulfonamidesIBA 01/2021

Therapy/Procedure

6	Therapeutics 12/2023 - 03/2010
5	Immunotherapy 05/2024 - 01/2018
2	Oral Administration 01/2019 - 11/2014
2	Transplantation 09/2011 - 01/2011
1	Cell- and Tissue-Based Therapy (Cell Therapy) 12/2023